GAMIMUNE N SUMMARY
Immune Globulin Intravenous (Human), 10% -- Gamimune® N, 10% treated with solvent/detergent is a sterile solution of human protein containing no preservative. Gamimune N, 10% consists of 9%-11% protein in 0.16-0.24 M glycine. Not less than 98% of the protein has the electrophoretic mobility of gamma globulin. Not less than 90% of the IgG is monomer. Also present are traces of IgA and of IgM. The distribution of IgG subclasses is similar to that found in normal serum. The measured buffer capacity is 35 mEq/L and the osmolality is 274 mOsmol/kg solvent.
Gamimune N, 10% is efficacious in the treatment of primary immunodeficiency states in which severe impairment of antibody forming capacity has been shown, such as: congenital agammaglobulinemias, common variable immunodeficiency, Wiskott-Aldrich syndrome, x-linked immunodeficiency with hyper IgM, and severe combined immunodeficiencies.5,21-23 Gamimune N, 10% is especially useful when high levels or rapid elevation of circulating antibodies are desired or when intramuscular injections are contraindicated.
In clinical situations in which a rapid rise in platelet count is needed to control bleeding or to allow a patient with ITP to undergo surgery, administration of Gamimune N, 10% should be considered.
Published Studies Related to Gamimune N (Immune Globulin)
Induction of HIV-1-specific mucosal immune responses following intramuscular
recombinant adenovirus serotype 26 HIV-1 vaccination of humans. 
humans... CONCLUSIONS: These data demonstrate that a single intramuscular administration of
Anatabine supplementation decreases thyroglobulin antibodies in patients with
chronic lymphocytic autoimmune (Hashimoto's) thyroiditis: a randomized controlled
clinical trial. 
studied... CONCLUSIONS: These results demonstrate an immunological effect of anatabine on
Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO):
a phase II double-blind placebo-controlled trial. 
biomarkers... CONCLUSIONS: These results confirm tolerability and safety of this novel
LADA and CARDS: a prospective study of clinical outcome in established
adult-onset autoimmune diabetes. 
CONCLUSIONS: Adult-onset autoimmune diabetes was prevalent, even in patients with
Evaluation of intravenous anthrax immune globulin for treatment of inhalation
Bacillus anthracis toxins can be neutralized by antibodies against protective
antigen (PA), a component of anthrax toxins. Anthrivig (human anthrax
immunoglobulin), also known as AIGIV, derived from plasma of humans immunized
with BioThrax (anthrax vaccine adsorbed), is under development for the treatment
of toxemia following exposure to anthrax spores.
Clinical Trials Related to Gamimune N (Immune Globulin)
Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage [Active, not recruiting]
Recurrent miscarriage is a prevalent reproductive problem that affects many couples who are
trying to establish a family. This clinical study will evaluate the effectiveness of
intravenous immunoglobulin (IVIG) in improving the live birth rate in couples who suffer from
secondary recurrent miscarriage. This study will help in providing an answer to the question
of whether IVIG is helpful in secondary recurrent miscarriage.
Multi-Drug Desensitization Protocol for Heart Transplant Candidates [Recruiting]
Background: Patients may develop antibodies (human leukocyte antigen [HLA] alloantibodies)
to other human tissues via pregnancy, transfusions or previous transplantation, which limits
the ability to find an acceptable donor heart for transplantation. Such patients are at high
risk for antibody mediated rejection, graft failure, and acute rejection (i. e. death). For
successful transplantation, patients must receive organs from donors who lack the HLA
antigens that correspond to their alloantibody specificities. No successful desensitization
strategy currently exists.
Purpose: To determine if desensitization by deletion of immunologic memory with a multi-drug
approach including anti-T and B cell therapies and anti-plasma cell therapy can effectively
eliminate or significantly reduce alloantibody levels and permit highly sensitized patients
to obtain a heart transplant. This therapy is anticipated to remove immunologic memory and
will require re-immunization.
Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS [Not yet recruiting]
An increasing body of evidence indicates that an immune basis might underline a number of
pediatric neuropsychiatric disorders. Research studies found a subgroup of children who had
Obsessive compulsive (OCD) and/or tic disorders following a Group A beta-hemolytic
streptococcal (GAS) infection. The subgroup is identified by the acronym, PANDAS (pediatric
autoimmune neuropsychiatric disorders associated with streptococcal infections. More
recently, several PANDAS variants have been described, including adult-onset variant. There
are many evidences that OCD/tic symptoms could be due to an immunologic reaction against
brain tissues following a streptococcal infection.
The purpose of this study is to know if sertraline (one of the SSRI approved by FDA to
improve OCD/tic symptoms in these patients) plus antibiotic (benzathine penicillin G or
azithromycin in case of penicillin allergy) is more effective than SSRI only.
Patients who will not respond to antibiotic will be treated with intravenous immunoglobulin
(IVIG) in order to inactivate the immune reaction versus brain tissues.(No treatment
response is based on the lack of a Y-BOCS score improvement of at least 35%).
- To determine the safety and efficacy of SSRI+AB compared to SSRI only.
- To test the safety and additional beneficial effects of high dose of IVIG on antibiotic
prophylaxis for the treatment of OCD symptoms in non-responders patients with PANDAS.
- Participants will be screened to obtain medical history and other information at
Neurologic and Psychiatric Sciences Department of Florence University Hospital and at
- Participants will receive a treatment of either SSRI+AB or SSRI+placebo for 12 weeks
(double-blind randomized trial)
- Patients who will not respond to AB will be admitted to the hospital to receive IVIG
for 5 days, for 5 consecutive months.
- Follow-up visits will take place 3 and 6 months after the first evaluation, followed by
6 months follow-ups for 3 additional years.
Blood samples (including blood cytokine determination), ECG, Doppler and 2-dimensional
echocardiogram EEG, imaging studies (2 tesla MRI), and other tests will be performed both
before and after the treatment with SSRI+AB or SSRI+placebo and in case also after IVIG